VANDA PHARMACEUTICALS INC (VNDA)
US9216591084 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 125.16M | 135.82M | 135.00M | 52.10M | 61.00M | |||
| Marketable Securities | 268.98M | 252.44M | 331.80M | 380.70M | 306.70M | |||
| Receivables | 36.71M | 34.16M | 33.50M | 32.50M | 30.00M | |||
| Inventories | 1.50M | 1.36M | 1.20M | 1.00M | 1.30M | |||
| Other Current Assets | 7.07M | 9.17M | 17.70M | 12.00M | 10.10M | |||
| Total Current Assets | 439.43M | 432.95M | 519.30M | 478.30M | 409.10M | |||
| Non-Current Assets | ||||||||
| PPE Net | 9.05M | 9.14M | 11.00M | 12.40M | 14.60M | |||
| Intangibles | 119.35M | 121.37M | 18.60M | 20.10M | 21.60M | |||
| Other Non-Current Assets | 84.86M | 84.98M | 85.40M | 83.00M | 88.20M | |||
| Total Non-Current Assets | 213.26M | 215.49M | 114.90M | 115.50M | 124.40M | |||
| TOTAL ASSETS | 652.68M | 648.44M | 634.20M | 593.80M | 533.50M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 91.11M | 85.29M | 86.50M | 68.50M | 59.80M | |||
| Accounts Payable | 2.24M | 2.41M | 5.00M | 5.90M | 5.80M | |||
| Other Current Liabilities | N/A | N/A | N/A | 0.00 | 400.00K | |||
| Total Current Liabilities | 93.34M | 87.70M | 91.40M | 74.40M | 65.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Other Non-Current Liabilities | 15.35M | 15.83M | 15.60M | 14.40M | 14.30M | |||
| Total Non-Current Liabilities | 15.35M | 15.83M | 15.60M | 14.50M | 14.30M | |||
| TOTAL LIABILITIES | 108.69M | 103.53M | 107.00M | 88.90M | 80.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -159.54M | -155.39M | -157.90M | -164.20M | -197.30M | |||
| Additional Paid In Capital | 703.86M | 700.27M | 686.20M | 669.20M | 650.30M | |||
| Common Shares | 58.00K | 58.00K | 100.00K | 100.00K | 100.00K | |||
| Other Shareholders' Equity | 2.00K | 21.00K | 0.00 | 0.00 | 100.00K | |||
| Shares Outstanding | 58.20M | 57.53M | 56.80M | 55.90M | 54.90M | |||
| Tangible Book Value per Share | 7.30 | 7.36 | 8.95 | 8.67 | 7.86 | |||
| Total Shareholders' Equity | 544.00M | 544.91M | 527.20M | 504.90M | 453.30M | |||
| TOTAL LIABILITIES AND EQUITY | 652.68M | 648.44M | 634.20M | 593.80M | 533.50M | |||
| Statistics | ||||||||
| Current Ratio | 4.71 | 4.94 | 5.68 | 6.43 | 6.21 | |||
| Return On Assets (ROA) | -0.75% | 0.39% | 0.99% | 5.59% | 4.37% | |||
| Return On Equity (ROE) | -0.90% | 0.46% | 1.19% | 6.58% | 5.14% | |||
| Return On Invested Capital (ROIC) | N/A | N/A | 0.92% | 9.43% | 5.76% | |||
| Return On Invested Capital Ex Cash (ROICexc) | N/A | N/A | 6.55% | 56.56% | 26.97% | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexcg) | N/A | N/A | 8.67% | 73.65% | 34.40% | |||
All data in USD